JP2007502808A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502808A5
JP2007502808A5 JP2006523697A JP2006523697A JP2007502808A5 JP 2007502808 A5 JP2007502808 A5 JP 2007502808A5 JP 2006523697 A JP2006523697 A JP 2006523697A JP 2006523697 A JP2006523697 A JP 2006523697A JP 2007502808 A5 JP2007502808 A5 JP 2007502808A5
Authority
JP
Japan
Prior art keywords
chlorophenyl
phenyl
aza
hydroxy
bicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006523697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002596 external-priority patent/WO2005018645A1/en
Publication of JP2007502808A publication Critical patent/JP2007502808A/ja
Publication of JP2007502808A5 publication Critical patent/JP2007502808A5/ja
Pending legal-status Critical Current

Links

JP2006523697A 2003-08-21 2004-08-09 哺乳類における依存症の予防と治療のための薬剤組成物 Pending JP2007502808A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49680303P 2003-08-21 2003-08-21
PCT/IB2004/002596 WO2005018645A1 (en) 2003-08-21 2004-08-09 A pharmaceutical composition for the prevention and treatment of addiction in a mammal

Publications (2)

Publication Number Publication Date
JP2007502808A JP2007502808A (ja) 2007-02-15
JP2007502808A5 true JP2007502808A5 (https=) 2007-08-16

Family

ID=34216038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523697A Pending JP2007502808A (ja) 2003-08-21 2004-08-09 哺乳類における依存症の予防と治療のための薬剤組成物

Country Status (7)

Country Link
US (1) US20050043327A1 (https=)
EP (1) EP1658082A1 (https=)
JP (1) JP2007502808A (https=)
BR (1) BRPI0413693A (https=)
CA (1) CA2536280A1 (https=)
MX (1) MXPA06002035A (https=)
WO (1) WO2005018645A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440059B1 (en) * 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
US7132426B2 (en) * 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2006305104B2 (en) * 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
JP5269795B2 (ja) * 2006-09-29 2013-08-21 グリーン・クロス・コーポレイション カンナビノイドcb1受容体アンタゴニストとしてのヘテロアリール−ピラゾール誘導体
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
JP3145620U (ja) 2008-07-30 2008-10-16 公二 平井 擬似嗜好物品
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
US9663463B2 (en) 2013-11-20 2017-05-30 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
KR20180004734A (ko) 2015-05-20 2018-01-12 가부시키가이샤산와카가쿠켄큐쇼 신규 3-아자비시클로[3.1.0]헥산 유도체의 염의 결정 및 그의 의약 용도
CA3036382A1 (en) * 2016-12-21 2018-06-28 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
CN110352055A (zh) * 2017-03-02 2019-10-18 株式会社三和化学研究所 酒精使用障碍的治疗药物
SG11202007422QA (en) * 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
WO2023064228A1 (en) * 2021-10-11 2023-04-20 Anebulo Pharmaceuticals, Inc. Method of treating addiction
AU2022362107A1 (en) 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1440059B1 (en) * 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
AU2003267728A1 (en) * 2002-10-18 2004-05-04 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof

Similar Documents

Publication Publication Date Title
JP2007502808A5 (https=)
US7501405B2 (en) Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
WO2004089416A2 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US20090264412A1 (en) Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist Therapy
US20050043327A1 (en) Pharmaceutical composition for the prevention and treatment of addiction in a mammal
EP1615667A2 (en) Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
JP6185574B2 (ja) 耳鳴りを治療するためのh4受容体阻害剤
JP2012532152A5 (https=)
EP2010177A2 (en) Combination histamine h1r and h4r antagonist therapy for treating pruritus
JP2015512888A5 (https=)
AU2003212268A1 (en) Pharmaceutical composition of a PDE4 or PDE3/4 inhibitor and a histamine receptor antagonist
US10195195B2 (en) Selective histamine H4 receptor antagonists for the treatment of vestibular disorders
RU2005131497A (ru) Фармацевтическая композиция для предотвращения и лечения аддикции к никотину у млекопитающего
CA2524025A1 (en) A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
EP1862181A2 (en) Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1854487A2 (en) Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
EP1615666A2 (en) Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent